Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranquilon vs Afobazole in Anxiety Disorders due to Neurasthenia and Adjustment Disorders
NCT06843044Phase 4Recruiting
- Sponsor
- Valenta Pharm
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ranquilon in neurasthenia, adjustment disorder (AD), sponsored by Valenta Pharm. Started Jan 2025; status: recruiting.
02
Drugs
ranquilon
03
Conditions
neurastheniaadjustment disorder (AD)
Beyond the preview
Go deeper on NCT06843044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843044.